Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
Tazarotene by GRI Bio for Idiopathic Pulmonary Fibrosis: Likelihood of Approval
Tazarotene is under clinical development by GRI Bio and currently in Phase II for Idiopathic Pulmonary Fibrosis. According to GlobalData,...